WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Covaxin is not approved in the USA for any age group
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The phosphine ligand is available on the kilo scale for the first time, providing scientists with a powerful solution for cross-coupling chemistry
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
12-week certificate course commences on March 10th 2022
The product will be manufactured at Lupin’s facility in Pithampur, India
Subscribe To Our Newsletter & Stay Updated
